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Abstract
Background: Particulate matter air pollution has been associated with adverse health effects. The fraction of
ambient particles that are mainly responsible for the observed health effects is still a matter of controversy. Better
characterization of the health relevant particle fraction will have major implications for air quality policy since it will
determine which sources should be controlled.
The RUPIOH study, an EU-funded multicentre study, was designed to examine the distribution of various ambient
particle metrics in four European cities (Amsterdam, Athens, Birmingham, Helsinki) and assess their health effects in
participants with asthma or COPD, based on a detailed exposure assessment. In this paper the association of central
site measurements with respiratory symptoms and restriction of activities is examined.
Methods: At each centre a panel of participants with either asthma or COPD recorded respiratory symptoms and
restriction of activities in a diary for six months. Exposure assessment included simultaneous measurements of
coarse, fine and ultrafine particles at a central site. Data on gaseous pollutants were also collected. The associations
of the 24-hour average concentrations of air pollution indices with the health outcomes were assessed in a
hierarchical modelling approach. A city specific analysis controlling for potential confounders was followed by a
meta-analysis to provide overall effect estimates.
Results: A 10 μg/m3 increase in previous day coarse particles concentrations was positively associated with most
symptoms (an increase of 0.6 to 0.7% in average) and limitation in walking (OR= 1.076, 95% CI: 1.026-1.128). Same day,
previous day and previous two days ozone concentrations were positively associated with cough (OR= 1.061, 95%
CI: 1.013-1.111; OR= 1.049, 95% CI: 1.016-1.083 and OR= 1.059, 95% CI: 1.027-1.091, respectively). No consistent associations
were observed between fine particle concentrations, nitrogen dioxide and respiratory health effects. As for particle
number concentrations negative association (mostly non-significant at the nominal level) was observed with most
symptoms whilst the positive association with limitation of activities did not reach the nominal level of significance.
Conclusions: The observed associations with coarse particles are in agreement with the findings of toxicological studies.
Together they suggest it is prudent to regulate also coarse particles in addition to fine particles.
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Background
Over the last decades numerous epidemiological studies
have clearly shown that urban air pollution can produce
a variety of adverse health effects [1,2]. Ambient particu-
late matter (PM) either characterized as the mass con-
centration of particles less than 10 μm (PM10) or less
than 2.5 μm (PM2.5) are considered to be the major cul-
prit. Therefore, current air quality standards or guide-
lines refer to PM10 and/or PM2.5 [3,4]. However, in
reality ambient PM is a mixture of coarse (2.5-10 μm),
PM2.5 (named also fine particles) and ultrafine (<0.1 μm)
particles generated from different processes, having vari-
able chemical composition and atmospheric behavior. It
should also be noted that although the ultrafine fraction
accounts for less than 1% of the mass of particulate mat-
ter, it represents the greatest proportion in terms of
number of particles (typically >80%) [5-7]. Furthermore,
the mechanism and the fraction of PM that are mainly
responsible for the observed health effects is a matter of
controversy [1]. In 1995 Seaton hypothesized that the
number of ultrafine particles may be a more health rele-
vant property than the usually measured mass of inhaled
PM10 and PM2.5 [8]. This is because of the greater sur-
face area available to react with epithelial and inflamma-
tory cells in the lung and because of the capacity of
ultrafine particles to penetrate deeper in the lung paren-
chyma, potentially reaching the circulation and exerting
adverse biological effects by releasing toxic free radicals
[8-11]. In meantime other studies were published, how-
ever, the role of ultrafine particles is still under discus-
sion [9,12-14].
The only systematic review of studies that have ana-
lysed fine and coarse PM jointly demonstrates that the
health effects of coarse particles are significant and
should not be overlooked [15]. Thus, special consider-
ation should be given to each fraction of the particles
and their effects on health. Better characterization of the
health relevant particle fraction will have major implica-
tions for air quality policy since it will determine which
sources should be controlled.
The RUPIOH (Relationship between Ultrafine and fine
Particulate matter in Indoor and Outdoor air and respira-
tory Health) is an EU-funded multicentre study designed
to examine the distribution of various particle metrics
both indoors and outdoors in four European cities and
assess their health effects in individuals with asthma or
chronic obstructive pulmonary disease (COPD), based on
a detailed exposure assessment. The study consisted of
two parts: i) the diary study in which participants were
asked to complete a daily diary for six months while
exposure was assessed based on a central site measure-
ments and ii) the intensive week measurements during
which, for each subject, more intensive health and expos-
ure measurements were conducted. In this paper, we
report the association of ambient PM10, PM2.5, coarse par-
ticle mass (PM10-2.5) and particle number concentrations
(PNC), measured at the central site, with respiratory
symptoms and limitation in activities due to breathing
problems in participants having either asthma or COPD
who have been followed for six months. Associations of
the health outcomes with gaseous air pollutants were also
examined based on data collected from existing national
monitoring networks in each country. The relationships
between central site outdoor, residential outdoor and in-
door concentrations, as well as the association between
outdoor and indoor exposure to fine and ultrafine parti-
cles and lung function in the same participants but based
on the intensive week measurements have been published
before [16-20].
Methods
Study design
In the context of RUPIOH, a multicentre study was con-
ducted from October 2002 to March 2004 in four European
metropolitan areas, namely, Amsterdam (The Netherlands),
Athens (Greece), Birmingham (United Kingdom) and
Helsinki (Finland). During the whole study period a cen-
tral site in each city was used to monitor particle mass
and PNC on a daily basis. At various locations covering
the entire metropolitan area, homes of participants with
either asthma or COPD were selected. The criteria for the
central site and homes selection have been described in
detail in a previous publication [17]. Respiratory health
status of each participant was monitored for six months
by a daily symptom diary. We used a staged entry of the
participants (based on the real date the participants started
to fill out the diaries) in order to increase the period of
data collection and thus, decrease the likelihood for un-
controlled factors or unexpected events to influence the
associations between air pollution and health [21]. In all
centres, participants were recruited between October 2002
and March 2004.
Study population
Inclusion criteria and recruitment procedures have been
described in detail before [19]. Briefly, in each city the
recruitment criteria for participants were age 35 or more,
a doctor diagnosis of either asthma (as defined by Global
Initiative for Asthma) or COPD (as defined by Global
Initiative for Chronic Obstructive Lung Disease) and hav-
ing had experienced respiratory symptoms in the past
12 months [22,23]. Especially, in the Netherlands some
patients who had not received a definite diagnosis of
asthma or COPD were classified as chronic non-specific
lung disease (CNSLD) as a relic of tradition (term previ-
ously used to indicate either asthma or COPD) [24].
Severe patients defined as those using relief bronchodilat-
ing medications more than three times per day or using
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nebulised bronchodilators or long-term oxygen therapy as
well as participants unable to perform a satisfactory spir-
ometry test were excluded from the study. An attempt was
made to select non-working, non-smoking patients living
in a non-smoking household to eliminate potential con-
founding by occupational exposures to airborne particles
and by environmental tobacco smoke. The same screening
questionnaire was used across the four centres to ascertain
eligibility. However, each centre was allowed to choose the
optimal subject recruitment method. Specifically, in
Amsterdam, the panelists were recruited through distribu-
tion of 10,000 information letters accompanied by screen-
ing questionnaires. Inclusion criteria were checked using
the returned screening questionnaires followed by partici-
pants’ homes’ visits. In Athens, subjects recruited through
local hospitals and pulmonary chest physicians were visited
at home by a pulmonologist (A.K.) and one of the investi-
gators of the exposure assessment team (I.K.) who checked
whether inclusion criteria were met. In Finland, subjects
were selected from the Helsinki Metropolitan Area
(including cities of Helsinki, Espoo and Vantaa) by placing
advertisement on two issues of the respiratory patient asso-
ciation magazine (circulation ~3500 households) and no-
tice boards of pulmonary disease clinics of four major
hospitals within the study area. Candidate subjects were
interviewed and screened by telephone and invited to an
information session when they met the criteria. In the
United Kingdom, potential study subjects living in the
greater area of Birmingham were selected from the Clinic
for Respiratory illnesses (CRI) database of respiratory
patients at the Heartlands Hospital. Privacy regulations
restricted the selections to only those that had given their
written consent to be approached for research studies.
Medical ethical clearance was acquired from the rele-
vant local medical ethics committees in all centres before
the start of the recruitment. Written informed consent
was obtained from each subject.
Symptom diary
The diary was based upon diaries used in previous stud-
ies of acute effects of air pollution such as the PEACE
study [21]. Although there is no real objective method of
validating symptoms, a previous study by Hoek et al.
provide evidence that symptoms, assessed with the same
diary, are reflected in lung function drops [25]. Partici-
pants were instructed to complete a daily record about
respiratory symptoms and medication taken “as needed”
for six months, grading shortness of breath, wheeze,
cough, phlegm and woken with breathing problems as
absent (0), slight (1), or moderate/severe (2). In addition,
they were asked about any limitation in performing daily
life activities categorized as vigorous (such as running,
lifting heavy objects, participating in strenuous sports),
moderate (such as moving a table, pushing a vacuum
cleaner, bowling or playing golf ), walking one block/
climbing one flight of stairs and leaving one’s home,
because of breathing problems. This limitation could be
reported in three grades: no limitation (0), yes, did activ-
ity slowly (1) and yes, avoided activity completely (2).
Questions on whether they have been outside the house
or town and for how long have also been included.
During the study period there was personal contact
with the participants once a month to collect the com-
pleted diary forms, discuss potential problems and keep
the motivation at a good level.
Air pollution exposure
Exposure assessment has been described in previous pub-
lications [16-18,20]. In brief, during the entire study period
(October 2002 to March 2004) in each city measurements
of PM2.5, PM10 and PNC were performed continuously at
a central site representing urban background levels [17].
The same type of condensation particle counter (TSI
3022A, TSI Inc., St. Paul, MN, USA) was used in each city
to monitor PNC. 24-hour average particle mass concen-
tration was measured with Harvard impactors for PM2.5
and PM10. Coarse particles concentrations were calculated
by subtracting PM2.5 from PM10. After weighing, the ab-
sorbance of the PM2.5 filters (a good surrogate for elemen-
tal carbon/soot) was determined using reflectometry. PNC
was transformed to “noon-to-noon” 24-hour means to
coincide with the PM2.5 measurements. Data on concen-
trations of other air pollutants (ozone, nitrogen dioxide)
and meteorology (air temperature, relative humidity) were
collected from existing national monitoring networks in
each country. We did not replace missing values in expo-
sures variables by imputation.
Confounder data
Time trend in health endpoints (e.g. fatigue in report-
ing), weather (outdoor temperature, relative humidity),
medication use and day of the week were taken into
account as potential confounders. Because of the staged
entry of participants, we evaluated two time variables:
calendar date (proxy for unmeasured confounders) and
day of study for a specific subject (possibly related to
fatigue).
Quality assurance/quality control
Air pollution and health measurements were performed
according to standard operating procedures (SOPs). A
training workshop was organized before the start of the
fieldwork and site visits were implemented during the
fieldwork to identify any deviations from SOPs.
Statistical analysis
Data analysis was done according to a predefined ana-
lysis plan. The symptom variables, initially coded as 0
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for no symptoms (absent), 1 for slight symptoms and 2
for moderate/severe symptoms, were dichotomised for
the analysis by setting 0 for no symptoms and 1 for
slight to moderate/severe symptoms. Each symptom was
analysed separately either as prevalent (irrespective of its
occurrence on the previous day) or incident (when that
symptom was reported to be absent on the previous
day). Medication use was coded as 0 (no medication)
versus 1 (intake of one or more doses) independently of
the initial medication group. Every person was included
in the analysis regardless of how many diary entries were
made. Moreover, diary entries were excluded when parti-
cipants had left the study area during the measurement
period. For every pollutant the following lags were evalu-
ated: lag 0, 1, 2 and the average of lag 0–6 days. Lag 0
was defined as the 24-hour period starting from noon of
the calendar day before the health response.
A hierarchical modelling approach was used. First, re-
gression models were fitted in each city separately to
allow specific control for seasonal effects, weather and
other potential confounders. Results of the individual
city analysis were used in a second stage analysis (meta-
analysis) to provide overall estimates [26]. We computed
both fixed and random effects combined estimates. Fur-
thermore, a chi-square test of heterogeneity of the four
city-specific estimates was computed.
We applied logistic regression to obtain centre-specific
effect estimates. A smooth function (natural splines with 6
degrees of freedom per year) of time was used to remove
the seasonal patterns and long time trends from the data.
Afterwards, same-day (lag 0) and previous-day (lag 1)
mean daily temperatures were introduced simultaneously
into the model. For both lags of temperature, a linear term
was compared with a smoothed function (natural splines)
with 2, 3 and 4 degrees of freedom and the model with the
lowest Akaike’s Information Criterion (AIC) was selected.
A linear term of relative humidity (lag 0) was added to the
model as another indicator of weather. Finally, indicator
variables for day of the week, medication use and individ-
ual differences in frequency of symptoms, were added to
the model. After setting up the baseline model, the effects
of the various lags of the pollutants were evaluated.
In the city specific analysis we fitted fixed effects mod-
els, described above, as well as random intercept logistic
regression models using “glmmPQL” function from
MASS library in R software, to take into account the
correlation among each subject’s measurements. Results
from the random effects analysis were very similar to
those derived from fixed effects. In a few cases though,
we faced convergence issues. This was even more the
case when we tested a first order autoregressive correl-
ation structure. The significance of the associations was
similar between random intercept models and the mod-
els incorporating an autoregressive term.
Because of the heterogeneity of the study population,
we repeated the analysis (for all air pollution measures)
for the subgroup of asthmatic patients. There were not
enough COPD patients to analyse these patients separ-
ately. We also fitted two pollutant models by including
simultaneously PM2.5 and PM10-2.5 in order to better
characterize which of the two components of PM10
(PM10-2.5 or PM2.5) was responsible for the observed
health effects.
Effect estimates are expressed as odds ratios (OR) for
an increase of 10 μg/m3 in PM10, 10 μg/m
3 in PM2.5,
10 μg/m3 in PM10-2.5, 10,000 particles/cm
3 for PNC and
1·10-5 m-1 for absorbance, in order to be comparable
with other studies. For gaseous pollutants the effect esti-
mates are expressed as OR for an increase of 10 μg/m3
in ozone and NO2 concentrations.All analyses were per-
formed using R software [27].
Results
Panel characteristics
A brief description of the study population is presented in
Table 1. Mean age and age range were about the same in
all cities. Three participants in Athens were slightly below
of the recruitment criterion of ≥35 years. In Amsterdam a
large group was reported to have CNSLD. Medication use
was high in the panels. Seventy seven per cent of the parti-
cipants (77%) used reliever medication. Use of “as needed
medication” was recorded in 26.5% of total person days in
Helsinki, 13.9% in Athens, 37.9% in Amsterdam and
59.7% in Birmingham. Twenty-nine participants (21%)
worked outside their home especially from Amsterdam
and Birmingham. Those who worked outside their home,
worked on average 19 h/week.
Symptoms
In total between 4,760 and 6,003 person days were avail-
able for analysis in the four cities. In Amsterdam, Athens
and Birmingham participants filled out the diary from
October 2002 to March 2004 whilst in Helsinki between
October 2002 and February 2004. Missing values (person
days) ranged between 9.4-15.1% in Amsterdam, 4.7-5.5%
in Athens, 8.7-8.8% in Birmingham and 8.6-12.1% in
Helsinki. Consistent with the composition of the panel,
fairly high symptom prevalence occurred during the
study period. Person days with severe symptoms were
low, except for cough and phlegm. There were small dif-
ferences between the cities (Table 2).
Air pollution concentrations
Helsinki had the lowest median concentrations for all
PM components whilst Athens had the highest. However,
maximum concentrations of PM2.5 were observed in
Amsterdam (103.4 μg/m3) and of PM10-2.5 (152.6 μg/m
3)
in Helsinki (Table 3).
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Air pollution effects on symptoms-limitation in activities
due to breathing problems
Prevalence analyses
We observed very small differences in fixed and random
effects combined estimates. In Tables 4 and 5 combined
odds ratios for the association of particulate matter indi-
ces, NO2, ozone and prevalence of symptoms and limita-
tion in activities are presented, using random effects
models adjusting for the above mentioned confounders
and “as needed” medication. When all participants were
included in the analysis as a total, we found that a
10 μg/m3 increase in PM10 was significantly associated
at the nominal level with shortness of breath in the lag 1
whilst the association in the lags 2 and 0 to 6 was of
borderline significance. However, none of the associa-
tions was significant for the asthma group. Significant
association was also observed for wheezing and limita-
tion in walking due to breathing problems (lag 1). The
association was driven by the PM10-2.5 component of
PM10 and much less by PM2.5. Coarse particles concen-
trations were positively associated with most symptom
and restriction of activities variables in lag1. In addition,
the modest correlations between PM10-2.5 and PM2.5
(0.08, 0.40, 0.35 and 0.13 for Amsterdam, Athens,
Birmingham and Helsinki respectively) did allow us to
apply a two-pollutant model in order to separate and
further evaluate the effects of the two components of
PM10. The magnitude of the associations for PM10-2.5
Table 1 Characteristics of four European panels of asthmatic/COPD patients
Helsinki Athens Amsterdam Birmingham
n=36a n= 35a n = 36a n= 29a
Male /Female 6 / 30 19 / 16 10 / 26 7 / 22
Asthma 3 / 28 6 / 13 3 / 8 6 / 21
COPD 3 / 1 12 / 3 2 / 7 1 / 0
Otherb 0 / 1 1 / 0 5 / 11 0 / 1
Agec 63.5 [36–85] 62.2 [33–84] 63.3 [46–77] 60.1 [37–76]
Asthma 62.9 [36–85] 55.7 [33–77] 62.8 [46–77] 59.6 [37–76]
COPD 65.0 [57–74] 68.7 [45–84] 63.7 [59–72] 53.0 -
Otherb 75.0 - 78.0 - 63.2 [46–77] 69.0 -
Asthma 31 (86%) 19 (54%) 11 (31%) 27 (93%)
COPD 4 (11%) 15 (43%) 9 (25%) 1 (3.5%)
Asthma+COPD 1 (3%) 1 (3%) 4 (11%) 1 (3.5%)
CNSLDd 0 (0%) 0 (0%) 12 (33%) 0 (0%)
Smoking status
Never smoker 26 (72%) 15 (43%) 13 (36%) 15 (52%)
Current 0 (0%) 1 (3%) 0 (0%) 3 (10%)
Ex-smoker 10 (28%) 19 (54%) 23 (64%) 11 (48%)
ETSe exposure at home 0 (0%) 5 (14.7%) 0 (0%) 1 (3.4%)
Medication use
Short acting β2-agonist 24 (67%) 9 (26%) 16 (44%) 28 (97%)
Reliever medicationf 29 (81%) 21 (62%) 25 (69%) 29 (100%)
Inhaled glucocorticosteroids 34 (94%) 28 (82%) 27 (75%) 24 (83%)
Oral glucocorticosteroids 5 (14%) 5 (15%) 6 (17%) 6 (21%)
On need medication use
Short acting β2-agonist 18 (50%) 8 (24%) 14 (39%) 28 (97%)
Reliever medicationf 22 (61%) 21 (62%) 18 (50%) 29 (100%)
Inhaled glucocorticosteroids 6 (17%) 18 (53%) 7 (19%) 5 (17%)
Oral glucocorticosteroids 3 (8%) 5 (15%) 4 (11%) 5 (17%)
a Total participants in panel.
b Asthma +COPD or chronic non-specific lung disease.
c Given as mean and [range].
d Chronic non-specific lung disease.
e Environmental tobacco smoke.
f Includes short acting β2-agonist, long acting β2-agonist, anticholinergic drugs and combination of an anticholinergic drug and a β2-agonist.
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with prevalence of symptoms and restriction of activities
remained approximately the same or increased when we
applied a two-pollutant model with PM2.5 (Table 6).
The above-mentioned positive associations with PM10-2.5
(Tables 4 and 5) were reduced and no longer signifi-
cant after restricting the analysis to the asthmatic only
Table 2 Person days with symptoms in the diary (n =number of expected person days)
Helsinki Athens Amsterdam Birmingham
n=6480 % n=6300 % n=6480 % n=5220 %
Woken with breathing problems
No 4759 73.4 5334 84.7 4897 75.6 3953 75.7
Yes 978 15.1 667 10.6 958 14.8 808 15.5
Non response 743 11.5 299 4.7 625 9.6 459 8.8
Shortness of breath
No 3987 61.5 4891 77.7 3410 52.6 3111 59.6
Slight symptoms 1774 27.4 1015 16.1 2179 33.6 1443 27.6
Severe symptoms 140 2.2 96 1.5 284 4.4 206 4.0
Non response 579 8.9 298 4.7 607 9.4 460 8.8
Wheeze
No 4932 76.1 4325 68.7 4554 70.3 3182 61.0
Slight symptoms 923 14.2 1627 25.8 1102 17.0 1383 26.5
Severe symptoms 49 0.8 51 0.8 134 2.1 196 3.7
Non response 576 8.9 297 4.7 690 10.6 459 8.8
Cough
No 3418 52.8 4303 68.3 3251 50.1 2189 41.9
Slight symptoms 2305 35.6 1583 25.1 2234 34.5 2026 38.8
Severe symptoms 184 2.8 116 1.9 289 4.5 546 10.5
Non response 573 8.8 298 4.7 706 10.9 459 8.8
Phlegm
No 1973 30.5 3291 52.2 2957 45.6 2087 40.0
Slight symptoms 3462 53.4 2448 38.9 2597 40.1 2137 40.9
Severe symptoms 485 7.5 264 4.2 206 3.2 537 10.3
Non response 560 8.6 297 4.7 720 11.1 459 8.8
Limitation of vigorous activitiesa
No 3837 59.2 2716 43.1 3714 57.3 2663 51.0
Did activity slowly 1259 19.4 2661 42.2 897 13.8 988 18.9
Avoided activity completely 603 9.3 587 9.3 891 13.8 1113 21.3
Non response 781 12.1 336 5.4 978 15.1 456 8.8
Limitation of moderate activitiesa
No 3775 58.3 3928 62.3 4237 65.4 3420 65.5
Did activity slowly 2030 31.3 1874 29.8 1266 19.5 1211 23.2
Avoided activity completely 88 1.4 184 2.9 135 2.1 131 2.5
Non response 587 12.0 314 5.0 842 13.0 458 8.8
Limitation of walkinga
No 4867 75.1 3455 54.8 4449 68.7 3472 66.5
Did activity slowly 795 12.3 2438 38.7 1132 17.5 1228 23.5
Avoided activity completely 94 1.4 62 1.0 152 2.3 63 1.2
Non response 724 11.2 345 5.5 747 11.5 457 8.8
a due to breathing problems.
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participants. A significant association remained with res-
tricting walking activities and wheeze (borderline).
Ozone was significantly associated with cough at lag 0,
lag 1, lag 2 and with woken with breathing problems at
lag 0. Furthermore, the associations with wheezing, limi-
tation in vigorous activities and walking due to breathing
problems remained positive across all examined lags al-
though, non significant. Negative but non significant
associations were observed with shortness of breath
across all examined lags. However, a significant prevent-
ive effect of ozone for shortness of breath was revealed
for lags 1 and 2, in the asthma group. Moreover, in the
asthmatics, negative associations were also observed for
ozone with woken with breathing problems (lag 0), wheez-
ing (lag 0 and lag 1), and with limitation in activities due
to breathing problems (most of the lags), although non
significant (Tables 4 and 5).
Neither PM2.5 nor NO2 were consistently associated
with any symptom or limitation in activities variable. As
for PNC a (mostly non-significant) negative association
was observed with most symptoms whilst the positive
associations with woken with breathing problems and
cough in lag 1 as well as in limitation of activities due to
breathing problems (mainly vigorous and moderate) in
lags 0, 1, 2 did not reach the nominal level of significance.
Moreover, for PNC a change of the negative associations
with woken with breathing problems towards positive
values, across all lags, was observed when the analysis was
restricted to the asthmatic participants, although non sig-
nificant (Tables 4 and 5).
Centre specific and overall effect estimates with 95
percent confidence intervals (95% CI) for the association
of each symptom and air pollutant in lag1 are presented in
Figure 1. Odds ratios (OR) for the effect of PM10-2.5 were
consistently above one in almost every city as well as in
the pooled data using random effects meta-analysis.
Incidence analyses
Patterns similar to those in the combined prevalence
analyses were observed for the associations of incident
symptoms and particles especially the coarse fraction.
Shortness of breath was consistently associated with
PM10 and PM10-2.5 in lag 1 with no indication of hetero-
geneity between the centres (OR= 1.045, 95% CI: 1.008,
1.083 and OR= 1.065, 95% CI: 1.009, 1.124 respectively).
There was also a tendency towards positive associations
between PM10-2.5 and incidence of wheezing, cough and
limitation in walking but none of the associations were
statistically significant. Additionally, ozone was positively
associated with cough in lags 1 and 2 as well as the aver-
age lag 0–6 days but only in lag 2 the association
reached the nominal level of significance (Table 7).
Discussion
In this multicentre study we found consistent positive
associations between coarse particles central sites concen-
trations and prevalence of respiratory symptoms, as
recorded in a 6-month diary, in four panels of participants
with predominantly mild to moderate asthma or COPD in
four European cities participating in the RUPIOH study.
We also found a significant association of ozone with
cough and woken with breathing problems, but not with
other symptoms. Neither PM2.5 nor NO2 were consistently
associated with any symptom or limitation in activities
Table 3 Daily (24 hours noon-to-noon, central site) median air pollution concentration and meteorology in the four
cities
Helsinki Athens Amsterdam Birmingham
10/2002-4/2004 10/2002-3/2004 10/2002-3/2004 11/2002-3/2004
%
missing
Median Range %
missing
Median Range %
missing
Median Range %
missing
Median Range
PNC 104cm-3 5.0 1.3 (0.2, 4.4) 10.5 2.0 (0.3, 6.6) 2.4 1.8 (0.8, 4.4) 21.2 1.9 (0.2, 5.1)
PM10 μgm-3 38.1 12.4 (0.2, 156.4) 6.3 51.7 (8.5, 158.7) 3.3 26.6 (7.4, 126.0) 14.6 16.6 (2.8, 126.2)
PM2.5 μgm-3 34.6 7.4 (0.3, 33.2) 6.3 22.7 (2.4, 79.1) 3.1 16.7 (4.0, 103.4) 12.8 8.4 (0.7, 71.9)
PM10-2.5 μgm-3 39.1 4.6 (0.0, 152.6) 6.7 28.8 (0.7, 126.4) 3.7 9.4 (0.9, 24.2) 15.6 6.9 (0.3, 118.9)
Absorbance 10-5m-1 38.9 1.2 (0.2, 3.8) 6.3 3.5 (0.9, 8.4) 3.1 1.9 (0.5, 7.2) 12.8 1.3 (0.2, 4.9)
NO2 μgm-3 1.4 22.7 (4.5, 77.9) 27.4 39.9 (11.8, 110.9) 0.4 38.4 (10.4, 97.3) 0.2 34.4 (7.3, 83.3)
Ozone μgm-3 1.7 42.5 (4.1, 93.2) 11.8 46.9 (4.7, 108.2) 9.4 33.1 (0.9, 104.3) 0.0 37.3 (0.9, 106.6)
Temperature °C 0.0 2.0 (−22.8, 25.6) 0.0 15.0 (−3.1, 33.2) 0.0 9.1 (−6.1, 25.3) 0.0 9.2 (−1.4, 26.9)
Rel. humidity % 0.0 80.7 (36.5, 100.0) 0.0 66.1 (21.8, 93.2) 0.0 80.8 (38.5, 98.7) 0.0 79.3 (45.8, 97.9)
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Table 4 Associations of particulate matter indices, NO2 and O3 with prevalence of symptoms in all participants and the
subgroup of asthmatics (random effects pooled estimates)
Symptom Pollutant Lag0 Lag1 Lag2 Lag06
OR 95% CI OR 95% CI OR 95% CI OR 95% CI
Woken with breathing problems
PM10
Total 1.001 0.966-1.037 1.010 0.964-1.059 0.978 0.928-1.030 1.009 0.881-1.155
Asthmatics 0.977 0.937-1.019 0.982 0.923-1.044 0.953 0.881-1.031 0.947 0.855-1.049
PM2.5
Total 0.997 0.952-1.044 0.980 0.915-1.049 0.953 0.886-1.025 0.889 0.682-1.160
Asthmatics 0.988 0.932-1.048 0.955 0.863-1.057 0.944 0.868-1.026 0.943 0.787-1.130
PM10 - 2.5
Total 1.020 0.883-1.179 1.047 0.989-1.109 0.996 0.935-1.062 1.019 0.860-1.208
Asthmatics 0.959 0.797-1.154 1.009 0.952-1.070 0.915 0.731-1.147 0.689 0.381-1.247
PNC
Total 0.971 0.865-1.090 1.027 0.952-1.109 0.958 0.863-1.064 0.910 0.638-1.298
Asthmatics 1.012 0.844-1.212 1.047 0.961-1.141 1.019 0.939-1.106 1.195 0.953-1.497
Absorbance
Total 1.014 0.952-1.079 1.018 0.966-1.073 0.971 0.922-1.022 0.929 0.777-1.111
Asthmatics 1.051 0.874-1.264 1.026 0.940-1.120 0.978 0.916-1.044 0.967 0.805-1.162
NO2
Total 0.980 0.940-1.021 0.983 0.943-1.026 0.970 0.926-1.016 0.969 0.856-1.098
Asthmatics 1.017 0.918-1.126 0.995 0.935-1.059 0.964 0.918-1.012 0.984 0.850-1.140
O3
Total 1.063 1.020-1.108 1.023 0.957-1.094 1.010 0.959-1.064 1.037 0.896-1.200
Asthmatics 0.982 0.896-1.077 1.001 0.925-1.082 1.009 0.926-1.099 1.075 0.935-1.235
Shortness of breath
PM10
Total 0.998 0.970-1.026 1.037 1.002-1.074 1.014 0.986-1.042 1.050 0.998-1.106
Asthmatics 0.992 0.956-1.028 1.030 0.994-1.067 0.997 0.962-1.032 1.049 0.936-1.176
PM2.5
Total 1.001 0.942-1.063 1.035 0.974-1.099 1.026 0.984-1.070 1.027 0.944-1.117
Asthmatics 1.006 0.951-1.063 1.032 0.977-1.091 1.018 0.965-1.074 1.005 0.828-1.219
PM10 - 2.5
Total 0.995 0.949-1.042 1.060 1.015-1.107 1.002 0.949-1.057 1.044 0.947-1.151
Asthmatics 0.972 0.915-1.031 1.028 0.973-1.086 0.978 0.925-1.033 1.010 0.872-1.168
PNC
Total 0.972 0.901-1.048 0.910 0.844-0.982 0.919 0.860-0.982 0.908 0.770-1.071
Asthmatics 0.976 0.898-1.062 0.925 0.817-1.046 0.952 0.879-1.031 1.032 0.860-1.237
Absorbance
Total 1.019 0.936-1.109 1.042 0.954-1.138 1.026 0.978-1.077 1.064 0.929-1.218
Asthmatics 1.014 0.930-1.106 1.055 0.975-1.143 1.048 0.985-1.116 1.218 0.950-1.562
NO2
Total 1.011 0.934-1.094 0.996 0.915-1.085 0.985 0.940-1.032 1.011 0.874-1.170
Asthmatics 0.991 0.886-1.108 0.987 0.880-1.106 0.984 0.915-1.058 1.013 0.846-1.213
O3
Total 0.988 0.957-1.021 0.961 0.921-1.003 0.975 0.946-1.004 0.962 0.914-1.014
Asthmatics 0.967 0.931-1.004 0.932 0.898-0.967 0.932 0.888-0.979 0.915 0.828-1.011
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Table 4 Associations of particulate matter indices, NO2 and O3 with prevalence of symptoms in all participants and the
subgroup of asthmatics (random effects pooled estimates) (Continued)
Wheezing
PM10
Total 1.026 0.980-1.074 1.027 1.000-1.055 1.011 0.981-1.041 0.989 0.869-1.125
Asthmatics 1.012 0.955-1.073 1.011 0.979-1.043 0.994 0.964-1.026 0.984 0.894-1.082
PM2.5
Total 0.998 0.925-1.077 1.004 0.931-1.082 0.982 0.882-1.094 0.873 0.629-1.213
Asthmatics 0.971 0.886-1.064 0.966 0.888-1.050 0.973 0.886-1.067 0.902 0.681-1.195
PM10 - 2.5
Total 1.041 0.990-1.094 1.073 1.028-1.120 1.023 0.980-1.068 1.053 0.966-1.147
Asthmatics 1.045 0.972-1.124 1.044 0.995-1.096 1.003 0.957-1.051 1.008 0.909-1.119
PNC
Total 0.934 0.791-1.104 0.947 0.816-1.099 0.985 0.841-1.154 1.092 0.639-1.865
Asthmatics 0.975 0.815-1.165 0.989 0.821-1.191 1.046 0.842-1.301 1.406 0.730-2.705
Absorbance
Total 0.980 0.910-1.055 1.000 0.930-1.075 0.999 0.888-1.123 0.926 0.644-1.332
Asthmatics 0.970 0.890-1.058 0.984 0.906-1.070 0.975 0.853-1.113 1.008 0.755-1.347
NO2
Total 0.995 0.922-1.074 0.983 0.923-1.047 1.003 0.933-1.078 1.004 0.828-1.217
Asthmatics 0.995 0.934-1.060 0.980 0.916-1.048 0.986 0.895-1.086 0.999 0.838-1.191
O3
Total 1.008 0.966-1.051 1.012 0.965-1.061 1.009 0.949-1.073 1.031 0.933-1.138
Asthmatics 0.985 0.948-1.025 0.998 0.959-1.038 1.046 0.947-1.156 1.060 0.916-1.228
Cough
PM10
Total 1.001 0.975-1.027 1.014 0.985-1.045 0.999 0.957-1.043 1.007 0.913-1.110
Asthmatics 0.993 0.952-1.034 0.991 0.956-1.026 0.989 0.935-1.047 0.969 0.900-1.043
PM2.5
Total 0.960 0.922-0.999 0.971 0.933-1.011 0.962 0.919-1.008 0.901 0.753-1.079
Asthmatics 0.940 0.847-1.042 0.949 0.884-1.019 0.946 0.879-1.019 0.918 0.761-1.107
PM10 - 2.5
Total 1.099 0.943-1.282 1.089 0.956-1.240 1.043 0.958-1.137 1.210 0.772-1.896
Asthmatics 1.016 0.966-1.069 1.024 0.974-1.076 1.003 0.912-1.103 1.005 0.902-1.120
PNC
Total 0.981 0.916-1.051 1.009 0.944-1.079 0.968 0.895-1.047 0.894 0.714-1.119
Asthmatics 0.979 0.906-1.058 0.972 0.900-1.050 0.918 0.807-1.044 0.824 0.618-1.098
Absorbance
Total 0.939 0.898-0.982 0.976 0.932-1.022 0.959 0.917-1.003 1.083 0.797-1.472
Asthmatics 0.937 0.833-1.054 0.976 0.892-1.068 0.942 0.891-0.997 1.078 0.782-1.486
NO2
Total 0.971 0.937-1.007 0.981 0.945-1.017 0.965 0.931-1.000 0.959 0.899-1.024
Asthmaticss 0.980 0.935-1.026 0.986 0.941-1.033 0.972 0.925-1.020 0.981 0.903-1.066
O3
Total 1.061 1.013-1.111 1.049 1.016-1.083 1.059 1.027-1.091 1.066 0.982-1.157
Asthmatics 1.062 1.016-1.110 1.051 1.002-1.102 1.058 1.022-1.095 1.106 0.939-1.302
Bold are significant pooled effects.
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Table 5 Associations of particulate matter indices, NO2 and O3 with limitation in activities due to breathing problems
in all participants and the subgroup of asthmatics (random effects pooled estimates)
Symptom Pollutant Lag0 Lag1 Lag2 Lag06
OR 95% CI OR 95% CI OR 95% CI OR 95% CI
Vigorous activities
PM10
Total 1.018 0.950-1.092 1.028 0.957-1.103 1.026 0.956-1.102 0.989 0.854-1.146
Asthmatics 0.987 0.869-1.121 1.006 0.873-1.158 1.010 0.873-1.168 0.924 0.726-1.177
PM2.5
Total 1.016 0.910-1.135 1.016 0.892-1.158 1.039 0.922-1.169 1.005 0.831-1.216
Asthmatics 0.992 0.856-1.150 0.995 0.843-1.174 1.019 0.858-1.211 0.944 0.743-1.198
PM10 - 2.5
Total 1.093 0.933-1.281 1.114 0.949-1.308 1.049 0.948-1.160 1.230 0.851-1.779
Asthmatics 0.980 0.817-1.175 1.005 0.816-1.238 1.019 0.919-1.130 0.956 0.612-1.494
PNC
Total 1.001 0.888-1.129 1.018 0.916-1.133 1.054 0.985-1.129 0.906 0.778-1.054
Asthmatics 0.979 0.895-1.070 1.014 0.924-1.112 1.065 0.976-1.163 0.927 0.748-1.149
Absorbance
Total 0.999 0.894-1.117 1.021 0.917-1.137 1.010 0.885-1.152 0.994 0.691-1.432
Asthmatics 1.031 0.924-1.151 1.063 0.938-1.206 1.069 0.919-1.243 0.984 0.643-1.507
NO2
Total 0.988 0.940-1.038 1.010 0.971-1.051 1.037 0.979-1.097 1.007 0.844-1.202
Asthmatics 0.995 0.916-1.081 1.028 0.960-1.100 1.046 0.945-1.158 0.942 0.713-1.245
O3
Total 1.033 0.935-1.141 1.031 0.946-1.124 1.024 0.932-1.125 1.107 0.879-1.394
Asthmatics 0.980 0.887-1.083 0.988 0.927-1.053 0.979 0.922-1.040 0.981 0.850-1.133
Moderate activities
PM10
Total 0.973 0.888-1.067 0.973 0.923-1.026 0.973 0.907-1.044 0.904 0.729-1.122
Asthmatics 0.946 0.818-1.094 0.958 0.857-1.071 0.979 0.897-1.069 0.859 0.680-1.086
PM2.5
Total 0.922 0.749-1.136 0.950 0.848-1.065 0.963 0.862-1.077 0.953 0.808-1.124
Asthmatics 0.896 0.712-1.126 0.979 0.839-1.142 0.965 0.846-1.102 0.938 0.762-1.154
PM10 - 2.5
Total 1.068 0.913-1.249 1.023 0.932-1.122 1.014 0.966-1.064 0.912 0.667-1.248
Asthmatics 1.000 0.943-1.062 0.987 0.932-1.045 1.007 0.955-1.062 0.727 0.411-1.289
PNC
Total 1.077 0.937-1.239 1.034 0.899-1.189 1.010 0.927-1.100 0.935 0.762-1.146
Asthmatics 1.075 0.977-1.183 1.025 0.922-1.139 1.016 0.873-1.184 0.835 0.680-1.025
Absorbance
Total 0.973 0.891-1.062 0.973 0.869-1.088 0.974 0.851-1.116 1.036 0.740-1.451
Asthmatics 0.994 0.871-1.135 0.993 0.854-1.155 0.984 0.814-1.190 0.985 0.618-1.570
NO2
Total 1.004 0.917-1.100 0.991 0.915-1.074 1.007 0.932-1.088 1.064 0.873-1.296
Asthmatics 1.004 0.897-1.123 0.988 0.886-1.100 1.000 0.889-1.125 0.999 0.718-1.390
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variable. As for PNC a (mostly non-significant) negative
association was observed with most symptoms whilst
positive associations with woken with breathing problems
and cough as well as with limitation of vigorous and mod-
erate activities due to breathing problems, did not reach
the nominal level of significance. Interestingly, for PNC a
change of the negative associations with woken with
breathing problems towards positive values, across all lags,
was observed when the analysis was restricted to the asth-
matic participants, although non significant at the nominal
level. An analysis of the asthmatic subgroup showed gen-
erally lower odds ratios for PM10-2.5.
One particularity and strength of the RUPIOH study is
the in depth assessment of particulate air pollution by
measuring PM10, PM2.5 (then deriving coarse particles),
filters absorbance as well as the number of ultrafine par-
ticles. Previous work from RUPIOH that included air
pollution monitoring for one week inside and directly
outside participants’ homes reported no association with
lung function [19]. As the authors stated a potential
explanation could be the high prevalence of medication
use, the short period of measurements (one week) that
limited the ability to assess lagged effects over several
days or absence of an effect. The high prevalence of
medication use may also have covered some associations
in the present study.
A limitation of the study is the inclusion of both COPD
and asthma patients. COPD and asthma are two diseases
with different underlying pathophysiological mechanisms
and day to day variability in their symptoms [22,23]. Mix-
ing of the two diseases does not create bias in the analysis
in the full population as we adjusted for differences in
health status between individuals. The generalizability of
the size of the effect estimates is more affected by the
population. Though asthma and COPD are different dis-
eases, we are not aware of studies that have demonstrated
differences in the magnitude of response to air pollution.
In our recently accepted paper in the same panel we did
not find any difference in the effect of PM10-2.5 on total
nitrate and nitrite concentrations in exhaled breath
Table 5 Associations of particulate matter indices, NO2 and O3 with limitation in activities due to breathing problems
in all participants and the subgroup of asthmatics (random effects pooled estimates) (Continued)
O3
Total 0.970 0.899-1.046 1.000 0.916-1.091 1.002 0.939-1.070 1.022 0.879-1.189
Asthmatics 0.940 0.874-1.012 0.979 0.901-1.064 0.979 0.921-1.041 1.007 0.812-1.250
Walking
PM10
Total 1.010 0.924-1.104 1.039 1.007-1.073 1.012 0.976-1.049 1.074 0.966-1.194
Asthmatics 1.009 0.921-1.105 1.055 1.018-1.094 1.023 0.987-1.061 1.009 0.823-1.237
PM2.5
Total 1.000 0.917-1.091 1.019 0.953-1.088 0.963 0.850-1.090 0.839 0.574-1.225
Asthmatics 1.008 0.882-1.152 1.097 1.032-1.167 1.078 1.013-1.147 0.934 0.663-1.316
PM10 - 2.5
Total 1.072 0.904-1.273 1.076 1.026-1.128 1.044 0.997-1.092 1.079 0.819-1.420
Asthmatics 1.012 0.884-1.159 1.060 1.005-1.119 1.013 0.959-1.069 0.911 0.554-1.499
PNC
Total 0.978 0.797-1.199 0.986 0.915-1.063 1.007 0.937-1.083 0.975 0.670-1.418
Asthmatics 0.906 0.798-1.029 1.010 0.921-1.106 1.013 0.928-1.106 0.804 0.658-0.981
Absorbance
Total 1.014 0.915-1.124 1.038 0.956-1.128 1.013 0.942-1.089 0.852 0.544-1.333
Asthmatics 1.036 0.939-1.143 1.100 1.031-1.174 1.078 0.965-1.204 0.942 0.610-1.456
NO2
Total 0.979 0.940-1.019 1.011 0.959-1.065 1.034 0.993-1.077 1.075 0.931-1.241
Asthmatics 0.988 0.924-1.057 1.048 0.967-1.136 1.076 0.968-1.196 1.093 0.886-1.349
O3
Total 1.012 0.975-1.050 1.004 0.961-1.048 1.020 0.983-1.059 1.038 0.971-1.109
Asthmatics 0.999 0.948-1.053 0.982 0.933-1.033 1.003 0.939-1.071 1.048 0.913-1.203
Bold are significant pooled effects.
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condensate (EBC NOx), a marker of oxidative stress be-
tween asthma and COPD patients [28]. In that study we
could evaluate disease status as the outcome was a con-
tinuous variable. Unfortunately, an analysis restricted to
COPD patients was not possible due to the small number of
COPD patients participating in Helsinki and Birmingham.
Hence, we also could not test whether the smaller PM10-2.5
effect in the asthmatic subgroup differed significantly from
the COPD subgroup.
Our coarse particle findings are however consistent
with the observation that in the RUPIOH study only the
PM10-2.5 concentration at central sites was significantly
associated with increased EBC NOx collected during the
same week as the spirometry [28]. EBC NOx has been
suggested as a reliable marker of oxidative stress [29-31].
The link between PM10-2.5 with oxidative stress and air-
way inflammation may explain the increase in respira-
tory symptoms we found.
In this study, we also report significant positive associa-
tions of ozone with cough throughout most of the exam-
ined lags both in the analysis of total participants and the
subgroup of the asthmatics that are consistent with previ-
ous epidemiological and toxicological studies [32]. In
addition, positive associations, but not significant in the
nominal level, were observed with most of symptoms
when total participants were included in the analysis.
However, when we restricted the analysis to the subgroup
of asthmatics, a significant preventive effect of ozone for
shortness of breath was revealed for lags 1 and 2. Negative
associations were also observed with woken with breath-
ing problems, wheezing and with limitation in activities
due to breathing problems, although non significant. Fac-
tors like high medication use, intrinsic differences in
responsiveness to ozone among individuals, adaptation to
ozone issues or other spurious effects may have been
responsible for these findings [32].
In the last two decades a substantial body of literature
has focused on the harmful health effects of PM10 and
PM2.5 [15,32]. As a result guideline values have been
recommended by the U.S. Environmental Protection
Agency and World Health Organization for both indica-
tors of PM pollution to protect public health [2,3]. How-
ever, from recent studies there is increasing evidence
that the health effects of coarse particles should not be
underestimated. In a systematic review of epidemio-
logical studies that have analyzed fine and coarse PM
Table 6 Associations of PM10-2.5 and PM2.5 with prevalence of symptoms and limitation in activities due to breathing
problems after applying two pollutant models (random effects pooled estimates)
Symptom Lag0 Lag1 Lag2 Lag06
OR 95% CI OR 95% CI OR 95% CI OR 95% CI
Woken with breathing problems
PM10 - 2.5 1.029 0.877-1.208 1.060 1.006-1.117 1.017 0.957-1.080 1.118 0.846-1.477
PM2.5 0.999 0.951-1.048 0.969 0.909-1.032 0.939 0.872-1.011 0.751 0.403-1.400
Shortness of breath
PM10 - 2.5 0.985 0.937-1.037 1.047 0.999-1.096 0.993 0.931-1.059 1.042 0.938-1.156
PM2.5 1.006 0.945-1.070 1.025 0.977-1.076 1.024 0.980-1.070 1.042 0.960-1.131
Wheezing
PM10 - 2.5 1.063 1.016-1.112 1.078 1.002-1.159 1.031 0.959-1.109 1.107 1.010-1.213
PM2.5 0.982 0.895-1.078 0.958 0.854-1.075 0.962 0.850-1.089 0.921 0.721-1.177
Cough
PM10 - 2.5 1.140 0.950-1.367 1.127 0.955-1.329 1.060 0.977-1.150 1.293 0.885-1.890
PM2.5 0.945 0.905-0.987 0.954 0.914-0.995 0.946 0.893-1.001 0.900 0.779-1.040
Vigorous activities
PM10 - 2.5 1.113 0.894-1.386 1.100 0.923-1.311 1.047 0.903-1.214 1.248 0.839-1.854
PM2.5 1.009 0.890-1.144 1.006 0.862-1.175 1.047 0.918-1.193 0.939 0.813-1.084
Moderate activities
PM10 - 2.5 1.097 0.891-1.350 1.036 0.917-1.170 1.006 0.956-1.059 0.965 0.699-1.333
PM2.5 0.919 0.748-1.129 0.950 0.844-1.070 0.967 0.873-1.070 0.937 0.797-1.103
Walking
PM10 - 2.5 1.090 0.900-1.321 1.073 1.020-1.128 1.047 0.990-1.107 1.128 0.946-1.344
PM2.5 0.998 0.950-1.049 1.001 0.937-1.071 0.969 0.862-1.088 0.790 0.466-1.339
Bold are significant pooled effects.
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jointly, Brunekreef and Forsberg examined the epidemio-
logical evidence for effects of coarse particles on health
[15]. They concluded that the effects of PM10-2.5 were
stronger than or as strong as PM2.5 on short-term re-
spiratory morbidity. Furthermore, in a national multicity
study, Zanobetti and Schwartz found a strong associ-
ation of both fine and coarse particles with daily deaths
in 112 U.S. cities [33]. A 10 μg/m3 increase in PM10-2.5
was significantly associated with total mortality, stroke,
cardiovascular, and respiratory mortality, the latter of
which showing the largest effect (a 1.2% increase). Mech-
anistically, these effects may be due either to biogenic fac-
tors or to metals carried by PM10-2.5 by activation of
inflammatory and oxidative stress pathways [34-36]. The
findings of our study support previous epidemiological
and toxicological evidence that health effects due to the
coarse fraction may be substantial [37].
The large number of calculations we have done could
have given some statistically significant associations by
chance. However, multiple testing is an unlikely explanation
of the findings in the current study. In the full study popu-
lation we found 14 significant associations of which 10
were positive; in the asthmatics subgroup we found 12 sig-
nificant associations of which 8 were positive. The
consistency of associations (e.g. for ozone and cough) fur-
ther argues against chance as the main explanation for our
findings. Additionally, in the full study population the sig-
nificant associations for PM10-2.5 were supported by ele-
vated though not nominally significant ORs for other lags
and symptoms. Finally, ORs were mainly homogeneous
across centers. Moreover, the modest correlations between
PM10-2.5 and PM2.5 did allow us to apply a two-pollutant
model in order to separate and further evaluate the effects
of the two components of PM10. The magnitude of the
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Figure 1 Odds ratio (95% CI) for prevalence of symptoms and limitation in activities associated with an increase of 10 μg/m3 in
previous day (lag1) concentrations of each pollutant (10,000/cm3 for PNC) in each participating city and overall estimate (random
effects pooled estimates).
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associations for PM10-2.5 with prevalence of symptoms and
restriction of activities remained approximately the same or
increased when we applied a two-pollutant model with
PM2.5.
The majority of studies that investigated health effects
of particulate pollutants have expressed results on a mass
basis. It has been suggested that when taking into consid-
eration particle number or surface area, the pulmonary
dose of toxic material related to PM2.5 may be much larger
than the dose related to PM10-2.5 that for this reason alone,
comparison on a mass basis may be less informative [15].
In our study we separately investigated the mass and the
number effect. Neither central site PM2.5 nor PNC were
consistently associated with symptoms. The association
we observed with PM10-2.5, if not by chance, may also
imply that a central measurement site is more appropriate
for measurements of mass concentrations than for PNC.
The analysis of RUPIOH data by Puustinen et al. showed
generally high correlations between 24 hour average cen-
tral site and residential outdoor concentrations for PM2.5
and soot with a lesser median correlation for PM10 and a
lower correlation for PNC and PM10-2.5 [17]. For PM10-2.5
correlations between central site and home outdoor mea-
surements were 0.66, 0.74, 0.89 and 0.64 in Helsinki,
Athens, Amsterdam and Birmingham respectively. A cen-
tral site thus provides a reasonably good estimate of more
local exposures even for coarse particles.
The relatively high divergence of PM10-2.5 concentra-
tions between proximate sites in the UK has recently been
confirmed by Liu and Harrison [38]. Consequently, for
Table 7 Associations of particulate matter indices, NO2 and O3 with incidence of symptoms in the four panels (random
effects pooled estimates)
Symptom Pollutant Lag0 Lag1 Lag2 Lag06
OR 95% CI OR 95% CI OR 95% CI OR 95% CI
Woken with breathing problems PM10 0.994 0.951-1.038 0.992 0.950-1.037 0.920 0.877-0.966 0.925 0.852-1.004
PM2.5 0.995 0.931-1.064 0.965 0.903-1.033 0.919 0.857-0.984 0.878 0.784-0.983
PM10 - 2.5 0.994 0.928-1.065 1.016 0.950-1.088 0.823 0.701-0.967 0.882 0.654-1.189
PNC 0.878 0.736-1.048 1.041 0.934-1.160 0.887 0.716-1.099 0.816 0.563-1.181
Absorbance 1.003 0.930-1.082 0.998 0.924-1.077 0.909 0.815-1.012 0.861 0.729-1.016
NO2 1.013 0.936-1.096 1.015 0.953-1.082 0.956 0.900-1.016 0.923 0.817-1.043
O3 1.016 0.912-1.131 0.988 0.937-1.041 0.994 0.945-1.045 1.069 0.980-1.165
Shortness of breath PM10 1.008 0.958-1.060 1.045 1.008-1.083 0.992 0.954-1.031 1.048 0.974-1.127
PM2.5 1.019 0.963-1.079 1.039 0.982-1.098 0.999 0.941-1.061 1.069 0.976-1.171
PM10 - 2.5 0.993 0.929-1.062 1.065 1.009-1.124 0.977 0.906-1.054 1.101 0.883-1.373
PNC 0.963 0.871-1.066 0.871 0.785-0.966 0.968 0.861-1.088 0.992 0.767-1.283
Absorbance 1.017 0.949-1.091 0.995 0.931-1.064 0.988 0.925-1.055 1.372 0.756-2.490
NO2 1.022 0.970-1.076 0.969 0.918-1.022 0.998 0.947-1.052 1.036 0.921-1.165
O3 0.989 0.945-1.035 0.987 0.944-1.031 1.021 0.980-1.065 1.021 0.950-1.097
Wheezing PM10 1.009 0.963-1.057 0.997 0.903-1.100 1.000 0.930-1.076 1.025 0.838-1.254
PM2.5 1.009 0.949-1.073 0.989 0.884-1.106 1.023 0.925-1.132 1.065 0.839-1.351
PM10 - 2.5 1.010 0.946-1.079 1.044 0.763-1.427 0.970 0.872-1.079 1.065 0.910-1.246
PNC 0.968 0.832-1.127 1.060 0.938-1.198 1.051 0.950-1.163 1.207 0.877-1.660
Absorbance 0.991 0.925-1.061 1.018 0.950-1.091 1.025 0.957-1.099 1.106 0.922-1.328
NO2 1.009 0.951-1.071 0.986 0.932-1.043 1.028 0.974-1.086 1.089 0.988-1.199
O3 0.968 0.921-1.017 0.978 0.899-1.064 0.975 0.931-1.022 0.940 0.861-1.026
Cough PM10 1.014 0.961-1.070 1.005 0.966-1.045 0.982 0.943-1.024 1.017 0.948-1.092
PM2.5 0.976 0.891-1.069 0.969 0.912-1.030 0.990 0.932-1.052 0.991 0.898-1.094
PM10 - 2.5 1.060 0.938-1.198 1.037 0.975-1.104 0.972 0.909-1.040 1.160 0.875-1.538
PNC 0.956 0.834-1.095 1.024 0.924-1.135 0.983 0.888-1.089 1.109 0.819-1.500
Absorbance 0.991 0.879-1.116 0.980 0.911-1.054 0.942 0.877-1.012 1.029 0.828-1.279
NO2 0.994 0.942-1.049 0.968 0.884-1.061 0.975 0.923-1.030 0.999 0.844-1.182
O3 0.984 0.939-1.032 1.027 0.950-1.109 1.044 1.000-1.090 1.030 0.938-1.132
Bold are significant pooled effects.
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both PNC and PM10-2.5, there is a higher probability of
exposure misclassification than for PM2.5 or soot. The
finding of significant associations with respiratory health
outcomes for PM10-2.5 but not for PNC is therefore quite
striking but consistent with the recent findings of a
time series study in London which found significant asso-
ciations between PNC and cardiovascular health outcomes
whilst PM mass metrics were associated with respiratory
outcomes [39]. A plausible explanation could be the exist-
ence of different biological and pathophysiological mechan-
isms through which PM10-2.5 and PNC exert their adverse
effects or different target organs. The results of recent toxi-
cological studies support the theory that PM10-2.5 exert their
effects at the site of deposition in the airways whereas PNC,
after crossing the alveolar epithelial barrier, enter into the
systemic circulation and affect cardiovascular function
[40,41]. This theory could explain the positive associations
we found between PM10-2.5 and respiratory symptoms.
In summary, our study contributes to the literature on
the health effects of PM in respiratory patients. More-
over, the results of our study are in agreement with the
findings of recent epidemiological and toxicological
studies and provide enough evidence to conclude that it
is prudent to keep PM10-2.5 regulated in addition to fine
particles.
Conclusions
Our study adds to the limited existing evidence of recent
epidemiological and toxicological studies that health
effects due to the coarse fraction of ambient PM may be
substantial. Further studies are needed to clarify possible
different effects of PM on COPD and asthmatic patients.
The observed associations suggest it is prudent to regu-
late also coarse particles in addition to fine particles.
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